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Addressing the Threat of 
Drug-Resistant Gonorrhea 
Antibiotic resistance is threatening the effectiveness of gonorrhea treatment in the United States. Gonorrhea is one of the 
most common sexually transmitted diseases (STDs), with more than 800,000 infections estimated to occur in the United 
States each year. Left untreated, it can cause serious health problems, particularly for women, including chronic pelvic pain, 
life-threatening ectopic pregnancy, and even infertility.  And while medication for gonorrhea has been available for decades, 
the bacteria has grown resistant to nearly every drug ever used to treat it. 
In response to the ongoing threat of drug resistance, CDC has repeatedly revised its gonorrhea treatment guidelines to 
phase out the use of antibiotics that have become less effective in treating the infection. In the United States today, only one 
recommended treatment option remains – a combination of the antibiotics azithromycin and ceftriaxone. 
CDC encourages providers to adhere to the recommended dual therapy treatment guidelines, and urges researchers in the 
public and private sectors to step up efforts to develop new treatments for this common but potentially serious STD. It’s 
also essential to maintain systems and services across the United States to prevent, diagnose and treat gonorrhea.  Effective 
diagnosis and treatment are essential to protect individual health and stop the spread of infection, including resistant strains. 
Gonorrhea Treatment: A Shrinking Arsenal 
Over the years, gonorrhea has developed resistance to nearly every drug ever used to treat it, including sulfonamides, 
penicillin, tetracycline, and fluoroquinolones. Due to widespread resistance to each of these antibiotics, by 2007, only 
cephalosporins — including the oral antibiotic cefixime and the injectable antibiotic ceftriaxone — were left to effectively 
treat gonorrhea. 
CDC’s Gonococcal Isolate Surveillance Project (GISP) closely monitors for early warning signs of resistance to recommended 
treatments. In 2012, after evidence from GISP suggested that resistance to cefixime was emerging, CDC issued new guidelines 
recommending against its use. Evidence indicates that this change helped slow the emergence of cephalosporin resistance, 
but only one recommended treatment option now remains: ceftriaxone injections combined with oral azithromycin. 
While this regimen continues to be effective, recent CDC data indicate that resistance to azithromycin is emerging. This 
information, coupled with past experience suggests our ability to cure people with gonorrhea will fade unless we take steps 
now to address growing antibiotic resistance. 
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Monitoring for Drug Resistance 
Since 1986, GISP has routinely monitored how Neisseria gonorrhoeae – the bacteria that causes gonorrhea – responds to
antibiotics. The surveillance system annually collects approximately 5-6,000 N. gonorrhoeae samples from men with urethral
gonorrhea at STD clinics in approximately 25-30 U.S. cities and measures the concentration of various antibiotics needed to stop
the bacteria’s growth in the laboratory. A “minimum inhibitory concentration” (MIC) is the lowest concentration of drug needed
to stop growth and is an indication of how susceptible the bacteria is to treatment with a given antibiotic. The higher the MIC,
the greater the dose of antibiotics required for effective treatment.  If MICs become too high, the antibiotic will not work at all. 
From 2013 through 2014 the percentage of samples with elevated MICs of azithromycin increased more than 300 percent 
(from 0.6 percent to 2.5 percent). This is the largest increase since monitoring for this drug began, and increases have occurred 
across the country. Gonorrhea remains more susceptible to azithromycin than to other antibiotics, such as penicillin (16.2 
percent with elevated MICs in 2014) or tetracycline (25.3 percent with elevated MICs in 2014), and azithromycin combined 
with ceftriaxone is still an effective treatment option for gonorrhea. However, the data suggest time may be running out.  
While the currently recommended treatment continues to be effective, there has been at least one reported case outside 
the cou try which required increased drug dosing to cure. Increased a tion to monitor for and prevent increased resistance 
is essential. 
STD Testing and Treatment Services are Vital for Containing the 
Threat of Antibiotic Resistant Gonorrhea 
Rates of gonorrhea and several other reportable STDs have been increasing nationwide in recent years. STD prevention 
services play a vital role in keeping antibiotic resistant gonorrhea, and other STDs, from flourishing in the community by 
providing critical testing and treatment options. With an estimated 20 million new sexually transmitted infections occurring 
each year, public health agencies cannot provide services to all those who need them. 
The public health and health care systems must work together. CDC is taking action by collaborating with state and local 
health departments to extend the reach of existing STD prevention services by providing testing services, medications 
and other resources to STD clinics and health departments, improving STD surveillance and electronic health records 
management, and training Disease Intervention Specialists for outbreak response. 
About Gonorrhea 
Of the more than 800,000 new infections every year, fewer than half are diagnosed – and CDC surveillance data indicates that 
after decades of declines, new infections are on the rise. 
If undiagnosed and untreated, gonorrhea can cause serious health problems. For women, it can increase their risk for a 
life-threatening ectopic pregnancy. And for men and women, the infection can cause conditions that can lead to infertility. 
Untreated gonorrhea can also increase a person’s risk of acquiring or transmitting HIV. And untreated gonorrhea may be 
transmitted to others, further accelerating the spread of infection and increasing the risk of an eventual treatment failure. 
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Improved Surveillance and Accelerated Drug Development 
Urgently Needed 
As part of the federal government’s broader Combating Antibiotic Resistant Bacteria (CARB) Action Plan, CDC specifically 
addresses the threat of antibiotic resistant gonorrhea by  strengthening the timeliness of surveillance systems, working 
with state and local health departments to enhance their capacity to monitor and test for resistant gonorrhea infections 
and developing rapid response strategies to effectively contain the spread of resistant gonorrhea, in the event that resistance 
is detected.  
Action from healthcare providers, state and local health departments, and public and private partners is urgently needed 
to prevent untreatable gonorrhea from becoming a reality: 
Healthcare Providers — Physicians and other healthcare providers are on the front lines in the fight against gonorrhea 

and play a critical role in our response. CDC encourages all providers to:

 • Take a sexual history. This will help you know which STDs to test your patient for and at which anatomic sites.
 •	 Adhere to CDC’s recommendations by always treating gonorrhea promptly with a combination of injectable 

ceftriaxone and oral azithromycin, including post-treatment testing to confirm cure when recommended 

(www.cdc.gov/std/treatment)

 • Follow key CDC screening recommendations, including: 
   
   
¡ Screen all sexually active women younger than 25 years, as well as older women with risk factors such as new or multiple 
sex partners, or a sex partner who has a sexually transmitted infection. 
¡ Screen sexually active MSM at anatomic sites of possible exposure at least annually. 
• Evaluate and treat all patients’ sex partners from the previous 60 days
 •	 Obtain cultures to test for decreased susceptibility from any patients with suspected or documented gonorrhea 

treatment failures

 •	 Report any suspected treatment failure to local or state public health officials within 24 hours, helping to ensure that any 
potential resistance is recognized early 
Health Departments and Laboratories — State and local health departments and other laboratories should enhance  or 
rebuild gonorrhea culture capacity so that antibiotic resistance testing can be performed to ensure resistant infections 
are quickly detected and reported. If antibiotic resistance testing cannot be performed locally, facilities should identify 
and partner with other labs that can perform such testing. Health departments should notify CDC of treatment failures 
immediately. Laboratories should also inform local or state public health officials of any isolates with decreased susceptibility 
to cephalosporins. 
Researchers and Drug Developers — CDC urges scientists and private-sector drug developers to prioritize the identification 
and study of effective new antibiotic treatments for gonorrhea. With few new drugs in the pipeline, it is important to 
accelerate research on new drugs or drug combinations now, as it takes years to bring new drugs to market. 
If you are a member of the news media and need more information, please visit www.cdc.gov/nchhstp/newsroom 
or contact the News Media Line at CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention 
404-639-8895 or NCHHSTPMediaTeam@cdc.gov. 
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